Literature DB >> 28684034

Present and past perspectives on Clostridium difficile infection.

D A Álvarez-Hernández1, A M González-Chávez2, D González-Hermosillo-Cornejo3, G A Franyuti-Kelly4, A Díaz-Girón-Gidi3, R Vázquez-López5.   

Abstract

Clostridium difficile is a Gram-positive bacillus that has become one of the main hospital-acquired human gastrointestinal infections in recent years. Its incidence is on the rise, involving more virulent strains, affecting new and previously uncontemplated groups of patients, and producing changes in clinical presentation and treatment response that influence disease outcome. Early diagnosis and disease stratification based on the severity of C.difficile infection are essential for therapeutic management and the implementation of containment measures. However, the speed at which new strains with greater pathogenicity are developing is surpassing that of the development of new drugs, making it necessary to validate other therapeutic options. The present article is a review of the epidemiologic, pathophysiologic, diagnostic, and therapeutic aspects of C.difficile infection, from its first isolation to the present date, that aims to contribute to the preparation of general physicians and specialists, so that patients with this infection receive opportune and quality medical attention.
Copyright © 2017 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Colitis pseudomembranosa; Megacolon tóxico; Pseudomembranous colitis; Toxic megacolon

Mesh:

Year:  2017        PMID: 28684034     DOI: 10.1016/j.rgmx.2017.03.004

Source DB:  PubMed          Journal:  Rev Gastroenterol Mex (Engl Ed)        ISSN: 2255-534X


  2 in total

1.  Exhausted PD-1+ TOX+ CD8+ T Cells Arise Only in Long-Term Experimental Trypanosoma cruzi Infection.

Authors:  Rosa Isela Gálvez; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

2.  Role of the PD-1/PD-L1 Pathway in Experimental Trypanosoma cruzi Infection and Potential Therapeutic Options.

Authors:  Yanina Arana; Rosa Isela Gálvez; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.